産品簡介:
Erastin 愛拉斯汀（鐵死亡激活劑）
産品關鍵詞：
Erastin 愛拉斯汀；Liproxstatin-1；鐵死亡抑制劑；(1S,3R)-RSL3；Ferroptosis inducer 鐵死亡誘導劑；FeRhoNox-1 (Fe2+indicator) 亞鐵離子熒光(guāng)探針；C11 BODIPY 581/591；CAS：571203-78-6；
産品信息
|
産品名稱
|
産品編号
|
CAS NO.
|
規格
|
價格（元）
|
|
Erastin愛拉斯汀（鐵死亡激活劑）
|
MZ5272-1MG
|
571203-78-6
|
1mg
|
680
|
|
Erastin愛拉斯汀（鐵死亡激活劑）
|
MZ5272-5MG-A
|
571203-78-6
|
5×1mg
|
2720
|
|
Erastin愛拉斯汀（鐵死亡激活劑）
|
MZ5272-5MG-B
|
571203-78-6
|
5mg
|
1350
|
|
Erastin愛拉斯汀（鐵死亡激活劑）
|
MZ5272-10MG
|
571203-78-6
|
10mg
|
2350
|
|
Erastin愛拉斯汀（鐵死亡激活劑）
|
MZ5272-50MG
|
571203-78-6
|
50mg
|
6350
|
産品描述
鐵死亡（Ferroptosis）是一(yī)種鐵依賴形式的非凋亡性細胞死亡。愛拉斯汀（Erastin）是一(yī)種鐵死亡激活劑（誘導劑）。體外誘導鐵死亡性細胞壞死，這一(yī)效應可被鐵死亡抑制劑（比如：Ferrostatin-1、Trolox、環匹羅司乙醇胺、放(fàng)線菌酮和β-巯基乙醇）所阻斷。HT-1080纖維肉瘤和Calu-1肺腫瘤細胞中，愛拉斯汀（5 µM）通(tōng)過谷氨酸-胱氨酸反向轉運體（System Xc-）抑制胱氨酸攝取；以及在酶結合的熒光(guāng)分析實驗中抑制谷氨酸釋放(fàng)。在表達Ras和SV40小(xiǎo)T腫瘤蛋白(bái)的細胞中選擇性誘導細胞死亡（IC50s
= 1.25-5 µg/ml）。
産品特性
|
化學名：2-[1-[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4(3H)-quinazolinone
|
|
CAS NO：571203-78-6
|
分子式：C30H31ClN4O4
|
分子量：547.04
|
外觀：固體
|
純度：≥98%
|
溶解性：溶于DMSO（≥5mg/ml，需要溫育助溶）、不溶于乙醇、不溶于水(shuǐ)
|
|
化學結構式：
|
保存與運輸方法
保存：-20ºC幹燥保存，至少2年(nián)有效。
運輸：冰袋運輸。
注意事(shì)項
1）
針對溶解性比較差的化合物(wù)，可通(tōng)過37℃孵育以及超聲的方式來促進其溶解。
2）
本品并非商業(yè)化的臨床藥物(wù)，僅用作科研用途，不得用作臨床診斷或治療，不得用于食品或藥品，絕對禁止用在人身上(shàng)。
3）
為(wèi)了您的安全和健康，請穿實驗服并戴一(yī)次性手套操作。
儲存液制備
|
質量
溶劑體積
濃度
|
1mg
|
5mg
|
10mg
|
|
1mM
|
1.8280 mL
|
9.1401 mL
|
18.2802 mL
|
|
5mM
|
0.3656 mL
|
1.8280 mL
|
3.6560 mL
|
|
10mM
|
0.1828 mL
|
0.9140 mL
|
1.8280 mL
|
【溫馨提示】：請根據産品在不同溶劑中的溶解度選擇合适的溶劑配制儲備液；本品在溶液狀态不穩定，建議現配現用。
使用方法【源自(zì)文獻，僅作參考】
|
文獻1，Liang, Z., Wu, Q., Wang, H. et al. Silencing of lncRNA
MALAT1 facilitates erastin-induced ferroptosis in endometriosis through
miR-145-5p/MUC1 signaling. Cell Death Discov. 8, 190 (2022). https://doi.org /10.1038/s41420-022-00975-w
體内研究（動物(wù)模型）：
動物(wù)模型（Animal Model）：Endometriosis
mouse model
實驗方法（Assay）：Seven-to-8-week-old C57BL/6 female mice were obtained and
17-β-estradiol-3-benzoate (30µg/kg) was administered to each
mouse every day for 3 days. We removed uterine horns from the donor mice and
added them to saline. Endometrium was cut into 1mm2 fragments. The endometrial fragments from
each uterine horn were suspended in 0.3ml saline and injected into the peritoneal cavities of
recipient mice with an 18-gauge needle. At 8 days (5 days after the
operation), endometrial-like lesions were established, and they were randomly
divided into two groups (each group contained 12 mice).In the experimental group, each mouse received erastin (20mg/kg/day) by intraperitoneal injection over a 7-day
period. In the control group, DMSO was used instead of erastin.At 15 days, the mice were sacrificed and endometriotic
lesions were collected.
|
|
文獻2，Huo H, Zhou Z, Qin J, Liu W, Wang B, Gu Y. Erastin Disrupts
Mitochondrial Permeability Transition Pore (mPTP) and Induces Apoptotic Death
of Colorectal Cancer Cells. PLoS One. 2016 May 12;11(5):
e0154605. doi:
10.1371/journal.pone.0154605. PMID: 27171435; PMCID: PMC4865238.
體内研究（動物(wù)模型）：
動物(wù)模型（Animal Model）：HT-29 tumor
bearing SCID mice
實驗方法（Assay）：Briefly, 2×106viable HT-29 cells in 100 μL of
growth medium (per mouse) were subcutaneously inoculated, and mice bearing
~100 mm3tumors were randomly divided into three groups with 10
mice per group.Mice were treated daily with 10
or 30 mg/kg body weight of erastin (intraperitoneal injection, for 4 weeks)
or vehicle control (Saline).
|
相(xiàng)關産品
|
貨号
|
名稱
|
規格
|
|
MZ5271-5MG
|
Ferrostatin-1鐵死亡抑制劑
|
5mg
|
|
MZ5272-5MG
|
Erastin鐵死亡激活劑
|
5mg
|
|
MZ5275-5MG
|
Liproxstatin-1鐵死亡抑制劑
|
5mg
|
|
MX4558-50UG
|
FeRhoNox-1 (Fe2+indicator)亞鐵離子熒光(guāng)探針
|
50μg
|
|
MX4559-24UG
|
FerroOrange (Fe2+indicator)亞鐵離子熒光(guāng)探針
|
24μg
|
|
MX4580-50nmol
|
FerroFarRed (Fe2+
indicator)亞鐵離子熒光(guāng)探針
|
50nmol
|
|
MX5211-1MG
|
C11 BODIPY 581/591脂質過氧化熒光(guāng)探針
|
1mg
|
— —Written/Edited by V.
Shallan【版權歸MKBio懋康所有】
上海夢澤生物科技有限公司是一(yī)家涉足于生(shēng)命科學和生(shēng)物(wù)技(jì)術(shù)領域研究的試劑、儀器(qì)和實驗室消耗品與實驗服務工(gōng)作，主要從(cóng)事(shì)細胞生(shēng)物(wù)學、植物(wù)學、分子生(shēng)物(wù)學、免疫學、生(shēng)物(wù)化學、蛋白(bái)組學。生(shēng)物(wù)制藥與診斷試劑研發生(shēng)産等領域。 本公司秉承“以人為(wèi)本，以誠為(wèi)信、合同守信”的經營理念。堅持"品質保障"的原則為(wèi)廣大客戶提供優質産品。
|
